Madrigal Pharmaceuticals, Inc. (MDGL)
546.93
+8.22
(+1.53%)
USD |
NASDAQ |
Sep 02, 16:00
546.45
-0.48
(-0.09%)
After-Hours: 20:00
Madrigal Pharmaceuticals Research and Development Expense (Annual) : 387.02M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 387.02M |
| December 31, 2024 | 235.62M |
| December 31, 2023 | 271.82M |
| December 31, 2022 | 244.97M |
| December 31, 2021 | 205.16M |
| December 31, 2020 | 184.81M |
| December 31, 2019 | 72.32M |
| December 31, 2018 | 25.39M |
| December 31, 2017 | 24.39M |
| December 31, 2016 | 15.93M |
| December 31, 2015 | 2.427M |
| December 31, 2014 | 68.20M |
| Date | Value |
|---|---|
| December 31, 2013 | 71.86M |
| December 31, 2012 | 49.41M |
| December 31, 2011 | 41.46M |
| December 31, 2010 | 40.25M |
| December 31, 2009 | 51.05M |
| December 31, 2008 | 81.58M |
| December 31, 2007 | 52.02M |
| December 31, 2006 | 50.50M |
| December 31, 2005 | 59.90M |
| December 31, 2004 | 38.14M |
| December 31, 2003 | 24.34M |
| December 31, 2002 | 7.292M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Exelixis, Inc. | 825.00M |
| Karyopharm Therapeutics, Inc. | 125.32M |
| ACADIA Pharmaceuticals, Inc. | 328.80M |
| Alnylam Pharmaceuticals, Inc. | 1.320B |
| Anika Therapeutics, Inc. | 25.77M |